Molecular Partners' Lead Radio-DARPin MP0712 Enters Clinic, FY25 Highlights Positive Pipeline Progress
MOLN sits 40% above its 52-week low of $3.36.
Summary
Molecular Partners announced its full year 2025 financial results and corporate highlights, primarily showcasing significant progress in its Radio-DARPin pipeline. The lead candidate, MP0712, targeting DLL3 for lung cancer, has officially entered a Phase 1/2a clinical trial, a major milestone for the company. Early imaging and dosimetry data for MP0712 from a Named Patient Access Program in South Africa showed specific tumor uptake and limited uptake in healthy tissues, supporting its clinical development. Additionally, the company's second Radio-DARPin program, MP0726, is progressing towards first-in-human imaging, and a non-exclusive development agreement with Eckert & Ziegler was established to expand isotope capabilities. While specific financial figures were not detailed in the announcement, the focus on advancing its clinical pipeline and securing partnerships is highly material for this clinical-stage biotech. Investors will be watching for initial clinical data from the MP0712 study, expected in 2026.
At the time of this announcement, MOLN was trading at $4.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $194M. The 52-week trading range was $3.36 to $5.36. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.